MTF2

Across TCGA pan-cancer cohorts, MTF2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MTF2 data layer compared with 30 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MTF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MTF2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, PDAC, and HNSC are the cancer types where MTF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	1.000	0.471	.002	36	view →
PDAC	OS	Quartile	II,III,IV	0.210	0.794	.024	14	view →
HNSC	OS	Tertile	III,IV	0.772	0.912	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MTF2–LSCC (DFS)

Open the LSCC breakdown →